Skip to main content
Erschienen in:

08.08.2019 | Review – Clinical Oncology

A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda

verfasst von: Jia Luo, Go Nishikawa, Vinay Prasad

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Since 1997, several monoclonal antibodies (mAbs) targeting the same receptor or its ligand have been approved for use in oncology. However, no studies have summarized head-to-head trials of these mAbs.

Methods

Systematic search of the biomedical literature and ClinicalTrials.gov for randomized studies comparing mAbs targeting the same receptor or its ligand that have been completed and published, completed and unpublished, or ongoing. We extracted trial characteristics including phase, indication, enrollment or target enrollment, randomization, primary endpoint and sponsor.

Results

Twenty-two approved cancer mAbs had at least one other approved mAb targeting the same receptor or its ligand, totaling 41 different oncology indications. These include 5 anti-CD20 mAbs, 5 anti-PD1/PDL1 mAbs, 4 anti-HER2 mAbs, 3 anti-EGFR mAbs, 3 anti-VEGF mAbs and 2 anti-IL6/IL6R mAbs. Seventeen were completed and published and 14 were unpublished or ongoing trials. The completed and published trials enrolled 11,373 patients and tested 13 mAbs (13/22, 59%). Additionally, 13 (76%) contained drugs manufactured by the same company and 13 (76%) reached conclusions felt to be favorable to the sponsor. Of the 14 ongoing/completed unpublished trials, there is a total target enrollment of 3404 patients with 9 mAbs tested. Of these, 86% (12/14) are testing mAbs manufactured by the same company and 71% (10/14) are sponsored by the company that made the drug being tested.

Conclusions

Most trials test drugs manufactured or sponsored by the same company. An overview of clinical trials agenda may lead to more uniform testing, helping clinicians make better evidence-informed prescribing decisions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Assouline S, Buccheri V, Delmer A et al (2016) Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 3(3):e128–e138CrossRefPubMed Assouline S, Buccheri V, Delmer A et al (2016) Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 3(3):e128–e138CrossRefPubMed
Zurück zum Zitat Buesching DP, Luce BR, Berger ML (2012) The role of private industry in pragmatic comparative effectiveness trials. J Comp Eff Res 1(2):147–156CrossRefPubMed Buesching DP, Luce BR, Berger ML (2012) The role of private industry in pragmatic comparative effectiveness trials. J Comp Eff Res 1(2):147–156CrossRefPubMed
Zurück zum Zitat Carlisle B, Demko N, Freeman G et al (2016) Benefit, risk, and outcomes in drug development: a systematic review of sunitinib. J Natl Cancer Inst 108(1):djv292CrossRefPubMed Carlisle B, Demko N, Freeman G et al (2016) Benefit, risk, and outcomes in drug development: a systematic review of sunitinib. J Natl Cancer Inst 108(1):djv292CrossRefPubMed
Zurück zum Zitat Davies A, Merli F, Mihaljevic B et al (2017) Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol 4(6):e272–e282CrossRefPubMed Davies A, Merli F, Mihaljevic B et al (2017) Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol 4(6):e272–e282CrossRefPubMed
Zurück zum Zitat Estellat C, Ravaud P (2012) Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 172(3):237–244CrossRefPubMed Estellat C, Ravaud P (2012) Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 172(3):237–244CrossRefPubMed
Zurück zum Zitat Flacco ME, Manzoli L, Boccia S et al (2015) Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol 68(7):811–820CrossRefPubMed Flacco ME, Manzoli L, Boccia S et al (2015) Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol 68(7):811–820CrossRefPubMed
Zurück zum Zitat Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32CrossRefPubMed Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32CrossRefPubMed
Zurück zum Zitat Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110CrossRefPubMed Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110CrossRefPubMed
Zurück zum Zitat Harbeck N, Gluz O, Christgen M et al (2017) De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the west german study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol 35(26):3046–3054CrossRefPubMed Harbeck N, Gluz O, Christgen M et al (2017) De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the west german study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol 35(26):3046–3054CrossRefPubMed
Zurück zum Zitat Hurvitz SA, Martin M, Symmans WF et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115–126CrossRefPubMed Hurvitz SA, Martin M, Symmans WF et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115–126CrossRefPubMed
Zurück zum Zitat Institute of Medicine (2009) Initial national priorities for comparative effectiveness research. The National Academies Press, Washington, DC Institute of Medicine (2009) Initial national priorities for comparative effectiveness research. The National Academies Press, Washington, DC
Zurück zum Zitat Lugtenburg P, Avivi I, Berenschot H et al (2017) Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica 102(11):1913–1922CrossRefPubMedPubMedCentral Lugtenburg P, Avivi I, Berenschot H et al (2017) Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica 102(11):1913–1922CrossRefPubMedPubMedCentral
Zurück zum Zitat Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331–1344CrossRefPubMed Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331–1344CrossRefPubMed
Zurück zum Zitat Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J (2017) Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review. PLoS Biol 15(2):e2000487CrossRefPubMedPubMedCentral Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J (2017) Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review. PLoS Biol 15(2):e2000487CrossRefPubMedPubMedCentral
Zurück zum Zitat Perez EA, Barrios C, Eiermann W et al (2017) Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol 35(2):141–148CrossRefPubMed Perez EA, Barrios C, Eiermann W et al (2017) Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol 35(2):141–148CrossRefPubMed
Zurück zum Zitat Price TJ, Peeters M, Kim TW et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 15(6):569–579CrossRefPubMed Price TJ, Peeters M, Kim TW et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 15(6):569–579CrossRefPubMed
Zurück zum Zitat Rugo HS, Barve A, Waller CF et al (2017) Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 317(1):37–47CrossRefPubMed Rugo HS, Barve A, Waller CF et al (2017) Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 317(1):37–47CrossRefPubMed
Zurück zum Zitat Rummel M, Kim TM, Aversa F et al (2017) Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol 28(4):836–842PubMed Rummel M, Kim TM, Aversa F et al (2017) Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol 28(4):836–842PubMed
Zurück zum Zitat Salar A, Avivi I, Bittner B et al (2014) Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol 32(17):1782–1791CrossRefPubMed Salar A, Avivi I, Bittner B et al (2014) Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol 32(17):1782–1791CrossRefPubMed
Zurück zum Zitat Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326(7387):472CrossRefPubMedPubMedCentral Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326(7387):472CrossRefPubMedPubMedCentral
Zurück zum Zitat Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 338:b1147CrossRefPubMedPubMedCentral Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 338:b1147CrossRefPubMedPubMedCentral
Zurück zum Zitat Tang J, Shalabi A, Hubbard-Lucey VM (2018) Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 29(1):84–91CrossRefPubMed Tang J, Shalabi A, Hubbard-Lucey VM (2018) Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 29(1):84–91CrossRefPubMed
Zurück zum Zitat van Imhoff GW, McMillan A, Matasar MJ et al (2017) Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol 35(5):544–551CrossRefPubMed van Imhoff GW, McMillan A, Matasar MJ et al (2017) Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol 35(5):544–551CrossRefPubMed
Zurück zum Zitat Vitolo U, Trneny M, Belada D et al (2017) Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 35(31):3529–3537CrossRefPubMed Vitolo U, Trneny M, Belada D et al (2017) Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 35(31):3529–3537CrossRefPubMed
Zurück zum Zitat Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463CrossRefPubMed Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463CrossRefPubMed
Metadaten
Titel
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda
verfasst von
Jia Luo
Go Nishikawa
Vinay Prasad
Publikationsdatum
08.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-02984-2

Weitere Artikel der Ausgabe 9/2019

Journal of Cancer Research and Clinical Oncology 9/2019 Zur Ausgabe

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.